TAK, US8740602052

Takeda Pharmaceutical stock reports Q1 revenue of JPY 1.22 trillion

Published on 09/29/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda Pharmaceutical stock enters the next launch cycle with Q1 core EPS of JPY 154, down 11.8 percent at constant exchange rates. Zasocitinib has a March 13, 2027 PDUFA date.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical stock was trading at EUR 16.05 at Lang & Schwarz on September 29, 2026 at 12:53 p.m. CEST. The company reported Q1 FY2026 core revenue of JPY 1.22 trillion, with currency effects masking a 0.5 percent decline at constant exchange rates, according to ScanX News on September 17, 2026.

Q1 revenue rises on currency

Takeda's reported revenue increased 10.2 percent on an actual foreign exchange basis in the first quarter of fiscal year 2026, reaching JPY 1.22 trillion, while core revenue fell 0.5 percent at constant exchange rates, ScanX News reported on September 17, 2026. The contrast makes the investor takeaway clear: exchange rates supported the headline number, while underlying growth remained constrained by mature products.

Core operating profit rose 11.5 percent on an actual-FX basis but declined 0.5 percent at constant exchange rates. Core EPS was JPY 154, down 11.8 percent at constant exchange rates, according to ScanX News.

Launch calendar shapes valuation

Takeda's near-term investment case is tied to newer medicines and regulatory milestones. As Investing.com reported on September 14, 2026, zasocitinib has a March 13, 2027 PDUFA date, while ORZEYFUL is awaiting US scheduling before a planned launch later in 2026.

The same conference update put peak sales guidance for zasocitinib at USD 3.0 billion to USD 6.0 billion for psoriasis and psoriatic arthritis. Takeda also plans a capital markets day in Tokyo on December 11, 2026, when management is expected to provide a broader strategic update, according to Investing.com.

Takeda stock stays in launch phase

MarketBeat said on September 4, 2026, that Zacks Research upgraded Takeda from hold to strong buy, while the broader rating mix remained Moderate Buy. The report also cited quarterly adjusted EPS of USD 0.95 against USD 0.41 consensus and revenue of USD 7.50 billion against USD 7.13 billion, putting the earnings comparison at the center of the stock discussion.

EUR 16.05 at Lang & Schwarz

Takeda Pharmaceutical stock was trading at EUR 16.05 at Lang & Schwarz on September 29, 2026 at 12:53 p.m. CEST. The quote page showed no valid prior-close comparison, so the article uses the current euro indication without a daily percentage.